Asia Breast Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis

Asia Breast Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis

Asia Breast Cancer Screening Market is projected to reach US$ 275.6 Million by 2028, according to Renub Research. Breast cancer stands as the prevailing cancer diagnosis among women and remains the primary cause of cancer-related fatalities in Asia. Breast cancer affects Asian women at an earlier age compared to their Western counterparts. In Asian countries, the peak age for breast cancer occurrence typically falls between 40 and 50 years, whereas in Western countries, it tends to be between 60 and 70 years. This disparity highlights the importance of considering regional and demographic factors when addressing breast cancer prevention, screening, and treatment strategies. Understanding these variations can help tailor healthcare approaches to effectively address the specific needs and challenges faced by different populations in combating breast cancer.

Asia Breast Cancer Screening Market is expected to grow at a CAGR of 4.15% from 2022 to 2028

Asia, the most populous and diverse continent, is home to approximately 4.75 billion people out of the world's total population of 8 billion. By 2050, the continent's population is expected to grow by an additional 1.8 billion individuals. This growth is a result of ongoing socioeconomic development and improved control of communicable diseases, leading to increased life expectancy across all Asian countries. As a consequence, the proportion of individuals aged 65 years and above is projected to double by 2030.

With cancer risk strongly linked to age, this demographic shift raises concerns about the escalating cancer burden and changing cancer patterns in Asian countries. Factors such as changing lifestyles, urbanization, reproductive patterns, dietary changes, obesity, tobacco use, alcohol consumption, chronic infections, and longer lifespans contribute to the rising cancer burden, particularly in low-resource and medium-resource countries in Asia.

Anticipated is the rise in awareness about breast cancer and promotion of optimal treatment through supportive measures by local governments and public organizations. Notably, Breast International Group (BIG) has partnered with the Breast Disease Professional Committee of CMEA (BDPCC) in China, the Korean Cancer Study Group (KCSG) in South Korea, and the Thai Society of Clinical Oncology (TSCO) in Thailand to facilitate research collaborations focused on breast cancer. These initiatives aim to enhance knowledge sharing and cooperation among experts, fostering advancements in breast cancer research and treatment for the benefit of patients in these regions. As a result, Asia Breast Cancer Screening Market was valued at US$ 216 Million in 2022.

With a focus on improving healthcare outcomes, China is poised to make significant strides in Asia breast cancer screening and prevention

By countries, Asia Breast Cancer Screening Market is breakup into India, China, Japan, Korea, Singapore, Thailand and Malaysia. The Breast Cancer Screening industry in China has witnessed significant growth and development. Factors such as increasing awareness about breast cancer, improving healthcare infrastructure, and rising government initiatives have contributed to this progress. The Chinese government has implemented screening programs and campaigns to promote early detection and treatment. Technological advancements have also played a crucial role, with the adoption of advanced imaging techniques like mammography and ultrasound. Moreover, collaborations between healthcare institutions, research organizations, and industry players have further propelled the growth of the Breast Cancer Screening industry in China.

With its rapid population growth trajectory, India is poised to make significant strides in the Asia Breast Cancer Mammography Screening industry

By Mammography Screening, Asia Breast Cancer Screening Market is segmented into China, India, Japan, Korea, Singapore, Thailand and Malaysia. India is emerging as the fastest-growing market in the Breast Cancer Mammography Screening industry. The country has witnessed a remarkable surge in breast cancer awareness and a growing emphasis on early detection. The Indian government, along with various healthcare organizations and NGOs, has implemented extensive screening programs and awareness campaigns across the nation.

Technological advancements in mammography imaging and increasing investments in healthcare infrastructure have further boosted the growth of the industry. With a rising population and changing lifestyles, the demand for breast cancer screening services in India is projected to continue its rapid expansion. India commitment to improving breast cancer diagnosis and treatment outcomes positions it as a key player in the global Breast Cancer Mammography Screening industry.

China is expected to witness a significant increase in its market presence in the Asia Breast Cancer MRI Screening industry

By MRI Screening, Asia Breast Cancer Screening Market is divided into China, Japan, India, Korea, Singapore, Thailand and Malaysia. China is poised to experience a surge in its market share within the Breast Cancer MRI Screening industry. The country expanding healthcare infrastructure, growing investments in advanced imaging technologies and increasing awareness about the importance of early breast cancer detection are driving this growth. The Chinese government has also implemented initiatives to improve access to breast cancer screening services, particularly in rural and underserved areas. Collaborations between domestic and international medical institutions, along with the involvement of leading industry players, are contributing to the development and adoption of state-of-the-art MRI screening technologies.

With its accelerating growth rate, China is poised to dominate the Asia Breast Cancer Ultrasound Screening industry

By Ultrasound Screening, Asia Breast Cancer Screening Market is classified into China, Japan, Korea, Singapore, India, Thailand and Malaysia. China is emerging as the fastest-growing market in the Breast Cancer Ultrasound Screening industry. The country's healthcare landscape has witnessed remarkable advancements in ultrasound technology, driving improved accuracy and efficiency in breast cancer diagnosis. Increasing awareness about the importance of early detection and screening has fueled the demand for ultrasound screening services in China. The government's initiatives to expand healthcare access, particularly in rural areas, have further contributed to the industry's rapid growth. Collaborations between healthcare providers, research institutions, and industry leaders have also played a significant role in fostering innovation and driving the adoption of advanced ultrasound screening solutions.

Key company

AstraZeneca, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health are key players in the Breast Cancer Ultrasound Screening industry in Asia. These companies are at the forefront of developing and providing advanced ultrasound screening solutions for breast cancer detection and diagnosis.

Renub Research report titled “Asia Breast Cancer Screening Market by Type (Mammography Screening, MRI Screening, and Ultrasound Screening) by Country (China, India, Japan, Korea, Singapore, Thailand and Malaysia) by Company Analysis (AstraZeneca, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health)” provides a complete analysis of Europe Breast Cancer Screening Industry.

Types – Market has been covered from 3 viewpoints

1. Mammography Screening
2. MRI Screening
3. Ultrasound Screening

Countries – 7 Asian Country Breast Cancer Screening Market has been Covered

1. China
2. India
3. Japan
4. Korea
5. Singapore
6. Thailand
7. Malaysia

Company Insights:

• Overview
• Recent Development
• Sales Analysis

Companies Covered in the Report:

1. AstraZeneca
2. Hologic Corporation
3. Becton
4. Siemens AG
5. Roche Diagnostics
6. Quest Diagnostics
7. Cardinal Health